A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals

Active
No
Status
Closed
Release Date
August 25th, 2023
Open Date
August 25th, 2023
Due Date(s)
November 14th, 2023
Close Date
November 14th, 2023
Topic No.
NIH/NIAID 126

Topic

Rapid Diagnostic Assays for Self-Monitoring of Acute or Rebound HIV-1 Infection

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: BOTHYear: 2023

Summary

The National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) are seeking proposals for Small Business Innovation Research (SBIR) contract proposals. The specific topic of the solicitation is "Rapid Diagnostic Assays for Self-Monitoring of Acute or Rebound HIV-1 Infection". The technology being solicited is focused on developing rapid diagnostic assays that can be used for self-monitoring of acute or rebound HIV-1 infection. The goal is to reduce the number of new HIV infections in the United States by 90 percent by 2030. The typical applications of this technology would be widespread HIV testing to reduce undiagnosed HIV infection and connect people to HIV medical care as soon as possible. This will improve the health of people living with HIV and prevent transmission. The solicitation is open for Phase I and Fast Track proposals, and direct-to-Phase II proposals will not be accepted. The anticipated number of awards is 4-5. The budget for Phase I is $300,000 for up to 2 years, and for Phase II, it is $1 million for up to 3 years. The deadline for proposal submission is November 14, 2023. For more information and to access the solicitation, visit the following links: - SBIR Topic Link: Link - Solicitation Agency URL: Link

Description

Phase I and Fast Track proposals will be accepted Direct-to-Phase II proposals will not be accepted Number of anticipated awards: 4-5 Budget (total costs): Phase I: $ 300,000 for up to 2 years Phase II: $ 1 million for up to 3 years Background An estimated 1.1 million people in the US are living with HIV, and one in seven are unaware of their infection. As a result, they are not accessing the care and treatment they need to stay healthy and reduce the likelihood of transmitting the virus to their partners. A US Government initiative, Ending the HIV Epidemic (https://www.hiv.gov/federal-response/ending-thehiv-epidemic/overview), and the National HIV/AIDS Strategy (https://www.hiv.gov/federal-response/national-hiv-aidsstrategy/national-hiv-aids-strategy-2022-2025#) seeks to reduce the number of new HIV infections in the United States by 90 percent by 2030. Part of this goal includes widespread HIV testing to reduce undiagnosed HIV infection and connect people to HIV medical care as soon as possible, which will improve the health of people living with HIV and prevent transmission. The small business innovation program is uniquely suited to reduce HIV incidence in the US because funds can only be spent domestically and not abroad